Kyorin Pharma Report issue

For profit Phase 1 Phase 2 Phase 4
Founded: Tokyo Japan (1923)
Status: No NME R&D (1923)

Organization Overview

First Clinical Trial
2007
NCT00512785
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Kyorin Pharmaceutical Co.,Ltd

Active Ingredients

Drugs in Phase 4 Trials (2)

fesoterodine (toviaz) (1 trial)

imidafenacin (2 trials)

Drugs in Phase 2 Trials (2)

Key: Kyorin Pharma (0) Acquired (2)

krp-104 (2 trials)

sitagliptin (januvia) (1 trial)

Drugs in Phase 1 Trials (2)

itraconazole (sporanox) (1 trial)

krp-a218 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 2 (Phase 2)

Urinary Bladder, Overactive (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 5
  • # of Trial APIs: 6